Protective effects of ATL146e and anti-CD1d treatments to reduce pulmonary inflammation in NY1DD. NY1DD mice were treated with either ATL146e (10 ng/kg/minute, 3 days), anti-CD1d (10 μg/g/day, 2 days), or a combination of both. All treatments resulted in significantly improved pulmonary parameters. (A-E) Representative H&E staining from sections of lungs at baseline illustrating reduced alveolar thickening and vaso-acclusion as a result of ATL146e or anti-CD1d treatment. (F-H) ATL146e or anti-CD1d treatment improved parameters of pulmonary function in NY1DD mice. Data were analyzed by 1-way ANOVA with Neuman-Keuls posttesting. P < .05, +NY1DD vs C57BL/6; *Different from NY1DD controls; # > anti-CD1d alone.